Latest news and press releases about Relay Therapeutics, Inc. (RLAY): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions.
Price
| Price | $18.84 |
| Market Cap | $4.1B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 4.29 |
| EV / EBITDA | -5.13 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -48.76% |
| Return on Invested Capital | -50.50% |
| Return on Assets | -44.50% |
| Gross Margin | -566.59% |
| Operating Margin | -2999.38% |
| Net Margin | -2763.64% |
Related companies: AMLX · CVAC · IMTX · INBX · NKTR · ORIC · SANA
Explore sector: Healthcare · Biotechnology
More sections of RLAY: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks